William Guyer Sells 8,233 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 8,233 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $35.99, for a total transaction of $296,305.67. Following the transaction, the insider directly owned 2,231 shares of the company’s stock, valued at approximately $80,293.69. This trade represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

William Guyer also recently made the following trade(s):

• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.87, for a total value of $817,400.00.
• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.18, for a total value of $703,600.00.

Corcept Therapeutics Trading Down 0.5%

CORT traded down $0.17 during midday trading on Friday, reaching $33.87. 1,230,010 shares of the company’s stock traded hands, compared to its average volume of 2,217,244. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The firm has a fifty day moving average of $40.56 and a two-hundred day moving average of $64.73. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of 41.31 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same period last year, the firm posted $0.26 earnings per share. Corcept Therapeutics’s quarterly revenue was up 11.1% on a year-over-year basis. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Corcept Therapeutics

Several large investors have recently made changes to their positions in CORT. Advisory Services Network LLC purchased a new stake in shares of Corcept Therapeutics in the 3rd quarter worth approximately $25,000. Clearstead Advisors LLC raised its stake in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 193 shares during the last quarter. Golden State Wealth Management LLC bought a new stake in Corcept Therapeutics in the second quarter worth $28,000. Hantz Financial Services Inc. grew its stake in shares of Corcept Therapeutics by 598.5% in the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 395 shares during the last quarter. Finally, Larson Financial Group LLC grew its stake in shares of Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 442 shares during the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: COR T’s Korlym revenue momentum: Zacks highlights a 13% Y/Y sales rise for Korlym in 2025 and projects 2026 revenue of $900M–$1B, suggesting solid underlying product sales even as competitive and legal risks persist. Korlym revenue article
• Neutral Sentiment: Short‑interest data published for early March appears inconsistent/zero (likely a data/reporting glitch) and does not provide clear evidence of increased shorting pressure at this time — investors should treat those figures cautiously. (Multiple short‑interest entries in news feed showed 0 shares / NaN changes.)
• Negative Sentiment: Hagens Berman and other firms: A securities class action (Allegheny County Employees’ Retirement System v. Corcept et al.) was flagged this week alleging the company and executives misled investors, citing FDA warnings and “evidence gaps” around the Relacorilant NDA that previously triggered a ~50% stock drop. Lead‑plaintiff deadline is April 21, 2026. Hagens Berman notice
• Negative Sentiment: Multiple plaintiff firms (Bronstein, Rosen, Pomerantz, Schall, Glancy, DJS, ClaimsFiler, etc.) have issued alerts encouraging investors to join/lead the class action based on purchases between Oct 31, 2024 and Dec 30, 2025 — this amplifies media attention and could increase settlement/defense costs and management distraction. Example: Bronstein notice. Bronstein notice
• Negative Sentiment: Schall/Rosen/Pomerantz & others reiterate class‑period and April 21 deadline; aggregated press releases increase likelihood of large plaintiff turnout and publicity — a material near‑term catalyst pressuring the stock. Example: Schall Law Firm reminder. Schall Law Firm notice

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. UBS Group began coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target on the stock. HC Wainwright cut their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Finally, Canaccord Genuity Group raised their target price on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $77.17.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.